<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927849</url>
  </required_header>
  <id_info>
    <org_study_id>hypertensive anal canal</org_study_id>
    <nct_id>NCT00927849</nct_id>
  </id_info>
  <brief_title>Idiopathic Hypertensive Anal Canal: a Place of Internal Sphincterotomy</brief_title>
  <official_title>Idiopathic Hypertensive Anal Canal: a Place of Internal Sphincterotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic hypertensive anal canal is a fact and already exists presented by anal pain
      aggravated by defecation. It can be managed safely by closed lateral sphincterotomy but
      chemical sphincterotomy had a minor role in its management.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient and methods: Sixty three patients complaining of anal pain without any anal pathology
      and 10 healthy volunteers were examined. All patients underwent clinical evaluation,
      neurological examination, anorectal manometry, and measurement of pudendal nerve terminal
      motor latency (PNTML). All patients with hypertensive anal canal were randomized into three
      groups. Group I (surgical group) underwent closed lateral sphincterotomy LS, group II using
      nitroglycerine ointment (GTN) and group III received injection of botulinum toxin in internal
      sphincter. Post procedures data were recorded at follow up period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Closed Lateral Sphincterotomy and Chemical Sphincterotomy on Hypertensive Anal Canal</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relieve of Anal Pain</measure>
    <time_frame>one year after the procedure</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Hypertensive Anal Canal</condition>
  <arm_group>
    <arm_group_label>surgical group lateral sphincterotomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>underwent closed lateral internal sphincterotomy (LIS) under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glycerin trinitrate group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>all were instructed to apply the Glycerin trinitrate group (GTN) ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>botulinum toxin injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All were injected with botulinum toxin injection (BTX- A) in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lateral internal sphincterotomy (LIS)</intervention_name>
    <description>closed lateral internal sphincterotomy was done under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.</description>
    <arm_group_label>surgical group lateral sphincterotomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycerin trinitrate (GTN)</intervention_name>
    <description>All were instructed to apply the GTN ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.</description>
    <arm_group_label>Glycerin trinitrate group</arm_group_label>
    <other_name>GTN ointment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>botulinum toxin injection (BTX A)</intervention_name>
    <description>All were injected with botulinum toxin injection (BTX- A) in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.</description>
    <arm_group_label>botulinum toxin injection</arm_group_label>
    <other_name>BTX A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients with hypertensive anal canal

        Exclusion Criteria:

          -  patients who had any pathological anorectal lesions such as anal fissure, piles,
             rectal prolapse, intussusception, anismus, cancer, patients with normal anal pressure

          -  patients who previously had anorectal surgery, chemical or surgical sphincterotomy,
             anal dilatation, IBD, venereal disease, neurological disorder or systemic
             gastrointestinal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>61 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ayman elnakeeb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ayman Elnakeeb</name>
      <address>
        <city>Mansoura</city>
        <zip>335111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://mans.edu.eg</url>
    <description>Mansoura university</description>
  </link>
  <results_reference>
    <citation>Aysan E, Aren A, Ayar E. A prospective, randomized, controlled trial of primary wound closure after lateral internal sphincterotomy. Am J Surg. 2004 Feb;187(2):291-4.</citation>
    <PMID>14769323</PMID>
  </results_reference>
  <results_reference>
    <citation>Brisinda G, Maria G, Bentivoglio AR, Cassetta E, Gui D, Albanese A. A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. N Engl J Med. 1999 Jul 8;341(2):65-9. Erratum in: N Engl J Med 1999 Aug 19;341(8):624.</citation>
    <PMID>10395629</PMID>
  </results_reference>
  <results_reference>
    <citation>Orsay C, Rakinic J, Perry WB, Hyman N, Buie D, Cataldo P, Newstead G, Dunn G, Rafferty J, Ellis CN, Shellito P, Gregorcyk S, Ternent C, Kilkenny J 3rd, Tjandra J, Ko C, Whiteford M, Nelson R; Standards Practice Task Force; American Society of Colon and Rectal Surgeons. Practice parameters for the management of anal fissures (revised). Dis Colon Rectum. 2004 Dec;47(12):2003-7.</citation>
    <PMID>15657647</PMID>
  </results_reference>
  <results_reference>
    <citation>Neill ME, Swash M. Chronic perianal pain: an unsolved problem. J R Soc Med. 1982 Feb;75(2):96-101.</citation>
    <PMID>7069679</PMID>
  </results_reference>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2009</study_first_submitted>
  <study_first_submitted_qc>May 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <results_first_submitted>March 23, 2009</results_first_submitted>
  <results_first_submitted_qc>May 7, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 25, 2009</results_first_posted>
  <last_update_submitted>May 7, 2009</last_update_submitted>
  <last_update_submitted_qc>May 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>ayman el nakeeb</name_title>
    <organization>Mansoura University hospital</organization>
  </responsible_party>
  <keyword>anal hypertonia</keyword>
  <keyword>sphincterotomy</keyword>
  <keyword>incontinence</keyword>
  <keyword>manometry</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Glycerol</mesh_term>
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>completed , mansoura university hospital</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Surgical Group Lateral Sphincterotomy</title>
          <description>underwent closed lateral internal sphincterotomy under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.</description>
        </group>
        <group group_id="P2">
          <title>Glycein Trinitrate Group</title>
          <description>(21) all were instructed to apply the GTN ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.</description>
        </group>
        <group group_id="P3">
          <title>Botilinium Toxin Injection</title>
          <description>All were injected with BTX- A in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Surgical Group Lateral Sphincterotomy</title>
          <description>underwent closed lateral internal sphincterotomy under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.</description>
        </group>
        <group group_id="B2">
          <title>Glycein Trinitrate Group</title>
          <description>(21) all were instructed to apply the GTN ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.</description>
        </group>
        <group group_id="B3">
          <title>Botilinium Toxin Injection</title>
          <description>All were injected with BTX- A in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="5.5"/>
                    <measurement group_id="B2" value="40" spread="7.5"/>
                    <measurement group_id="B3" value="40.5" spread="3.5"/>
                    <measurement group_id="B4" value="41" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Closed Lateral Sphincterotomy and Chemical Sphincterotomy on Hypertensive Anal Canal</title>
        <description>effect of closed lateral sphincterotomy and chemical sphincterotomy on hypertensive anal canal, anal manometery</description>
        <time_frame>one year</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Relieve of Anal Pain</title>
        <description>using a visual analog scale (VAS) with which each patients noted the severity of pain at each evaluated time using a linear between zero (no pain) and 10 ( severe pain)</description>
        <time_frame>one year after the procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Surgical Group Lateral Sphincterotomy</title>
            <description>underwent closed lateral internal sphincterotomy under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.</description>
          </group>
          <group group_id="O2">
            <title>Glycein Trinitrate Group</title>
            <description>(21) all were instructed to apply the GTN ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.</description>
          </group>
          <group group_id="O3">
            <title>Botilinium Toxin Injection</title>
            <description>All were injected with BTX- A in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.</description>
          </group>
        </group_list>
        <measure>
          <title>Relieve of Anal Pain</title>
          <description>using a visual analog scale (VAS) with which each patients noted the severity of pain at each evaluated time using a linear between zero (no pain) and 10 ( severe pain)</description>
          <units>score in scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" spread="2.32"/>
                    <measurement group_id="O2" value="4.18" spread="2.52"/>
                    <measurement group_id="O3" value="4.2" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Surgical Group Lateral Sphincterotomy</title>
          <description>underwent closed lateral internal sphincterotomy under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.</description>
        </group>
        <group group_id="E2">
          <title>Glycein Trinitrate Group</title>
          <description>(21) all were instructed to apply the GTN ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.</description>
        </group>
        <group group_id="E3">
          <title>Botilinium Toxin Injection</title>
          <description>All were injected with BTX- A in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.</description>
        </group>
      </group_list>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>ayman elnakeeb</name_or_title>
      <organization>Mansoura university hospital</organization>
      <phone>0020106752021</phone>
      <email>elnakeebayman@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

